UBS downgraded Pfizer Inc. (NYSE:PFE) to "neutral" from "buy" this morning, citing lower Covid-19 expectations. The analyst also slashed its price target to $47 from $55, noting the pharmaceutical giant's Covid estimates need to drop, while its broader pipeline upside is minimal in the near- to-mid-term. PFE was last seen 1.4% lower premarket in response. The stock has shed 12% already in 2023, and hasn't posted a weekly win in over a month.
In the options pits, short-term options traders are operating with a put-bias. This is per PFE's Schaeffer's put/call open interest ratio (SOIR) of 1.01, which stands higher than 87% of annual readings.
Now looks like a good time to speculate on PFE's next move with options. Pfizer stock's Schaeffer's Volatility Index (SVI) of 26% stands in the 13th percentile of readings from the past year, suggesting options traders are pricing in low volatility expectations right now.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.
Get This Free Report
